ROIV as reported
Roivant Sciences Ltd. reported $8.3M of revenue over the trailing twelve months, −72% on the year before. 9 reported series are charted on this page, each one as filed.
$8.3M
Revenue, trailing twelve months · to Q4 2025 · −72% against the twelve months before
- Net Income
- −$300M
Net Income · +74% year on year · trailing twelve months to Q4 2025
- Free Cash Flow
- −$768M
Free Cash Flow · −9.0% year on year · trailing twelve months to Q4 2025
- Op Margin
- −8278%
Op Margin · trailing twelve months to Q4 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $8.3M | −72% | Q4 2025 |
| Net Income | −$300M | +74% | Q4 2025 |
| EPS | −$0.54 | +116% | Q4 2025 |
| Op Margin | −8278% | n/a | Q4 2025 |
| Net Margin | −4699% | n/a | Q4 2025 |
| ROE | −11% | n/a | Q4 2025 |
| ROA | −9.5% | n/a | Q4 2025 |
| ROIC | 129% | n/a | Q1 2024 · 7 quarters behind |
| Free Cash Flow | −$768M | −9.0% | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Roivant Sciences Ltd. (ROIV) - Revenue & ProfitRevenue & ProfitRoivant Sciences Ltd. (ROIV)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
Ranks #77 of 145 by Smart Score